<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156249">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01724892</url>
  </required_header>
  <id_info>
    <org_study_id>othana001</org_study_id>
    <nct_id>NCT01724892</nct_id>
  </id_info>
  <brief_title>Comparison the Effects of Dexamethasone and Loteprednol on Epithelial Healing</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <authority>Thailand: Khon Kaen University Ethics Committee for Human Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corticosteroid has been used for the treatment after phototherapeutic keratectomy (PRK).
      Dexamethasone, a potent steroid can retard the corneal epithelial healing rate and has
      numerous serious complications, especially glaucoma. Loteprednol, a new generation of
      corticosteroid has less potency than dexamethasone and was proposed to has less side effect
      regarding intraocular pressure (IOP) elevation.  Therefore, Investigators would like to
      compare the effect of dexamethasone and loteprednol on corneal epithelial healing rate after
      PRK and risk of glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>corneal epithelial healing</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Epithelial Defect After Phototherapeutic Keratectomy</condition>
  <arm_group>
    <arm_group_label>Loteprednol etabonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Loteprednol etabonate eye drop 0.5%, 4 times a day, 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Dexamethasone eye drop 0.1%, 4 times a day, 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Loteprednol etabonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate</intervention_name>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the patient with epithelial defect after phototherapeutic keratectomy

        Exclusion Criteria:

          -  the patient with systemic disease such as diabetes and connective tissue disease

          -  the patient with ocular surface disease such as dry eye and recurrent corneal erosion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Onsiri Thanathanee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onsiri Thanathanee</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed?term=dexamethasone%20AND%20loteprednol</url>
  </link>
  <reference>
    <citation>Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol. 2012 Oct;32(5):507-17. Epub 2012 Jun 16. Review.</citation>
    <PMID>22707339</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 14, 2014</lastchanged_date>
  <firstreceived_date>November 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Onsiri Thanathanee</investigator_full_name>
    <investigator_title>othana</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Loteprednol etabonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
